4,5,6,7-四氢-1H-咪唑并[4,5-c]吡啶-6-羧酸甲酯 | 82523-06-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4,5,6,7-四氢-1H-咪唑并[4,5-c]吡啶-6-羧酸甲酯
• 英文名称: methyl 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylate
• 英文别名: methyl-4,5,6,7-tetrahydro-6-azabenzimidazole-5-carboxylate
• CAS: 82523-06-6
• 化学式: C₈H₁₁N₃O₂
• 分子量: 181.194
• InChiKey: RFEAQJBHALKQQR-UHFFFAOYSA-N

物化性质

• 熔点：
  142-144 °C (decomp)(Solv: methanol (67-56-1))
• 沸点：
  411.8±45.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4,5,6,7-四氢-1H-咪唑并[4,5-c]吡啶-6-羧酸甲酯 在 SeO₂ 作用下， 以 溶剂黄146 为溶剂， 生成 3H-咪唑并[4,5-C]吡啶-6-甲酸甲酯
  参考文献：
  名称：

  Thrombin inhibitors

  摘要：

  发明的化合物在抑制凝血酶和相关血栓闭塞方面具有以下结构：或其药学上可接受的盐，其中b为NY或O；c为CY2或N；d为CY3或N；e为CY4或N；f为CY5或N；g为CY6或N；Y4、Y5和Y6独立地为氢、C1-4烷基或卤素；Y1和Y2独立地为氢、C1-4烷基、C3-7环烷基、卤素、NH2、OH或C1-4烷氧基，Y3为氢、C1-4烷基、C3-7环烷基、卤素、—CN、NH2、OH或C1-4烷氧基；A为，并且W、W1、R1、R3、R4、R5、X和Z在规范中有定义。

  公开号：

  US06610692B1
• 作为产物：
  描述：

  L-组氨酸盐酸盐 在 盐酸 作用下， 以 水 为溶剂， 反应 4.0h， 生成 4,5,6,7-四氢-1H-咪唑并[4,5-c]吡啶-6-羧酸甲酯
  参考文献：
  名称：

  Biomimetic approach to potential benzodiazepine receptor agonists and antagonists

  摘要：

  Several beta-carbolines, isoquinolines, imidazopyridines , and canthin -6-ones prepared in biomimetic fashion were tested for their ability to bind to the benzodiazepine receptor. Methyl isoquinoline-3-carboxylate, methyl 6,7- dimethoxyisoquinoline -3-carboxylate (3b) 1-phenyl-3- carbomethoxyimidazopyridine , (6B,) and canthin -6- one ( 13a ) bound with moderate affinities, while 2- carbomethoxycanthin -6- one ( 13b ) bound to benzodiazepine receptors with an affinity comparable to several pharmacologically active benzodiazepines. The potency of 13b suggests that the benzodiazepine receptor(s) can tolerate substitution at positions 1 and 9 of a beta-carboline without loss of activity if the substituents are trigonal and maintain a planar topography. Moreover, displacement of the carbonyl group by two atoms from the aromatic ring (C) of the beta-carboline skeleton caused a marked decrease in binding to the benzodiazepine receptor. This observation supports the hypothesis that maximum binding affinity of beta-carbolines is achieved when the carbonyl group at position 3 is attached directly to the aromatic pyridine ring.

  DOI：

  10.1021/jm00371a002

文献信息

• [EN] NOVEL HDAC6 INHIBITORS AND THEIR USES<br/>[FR] NOUVEAUX INHIBITEURS DE HDAC6 ET LEURS UTILISATIONS
  申请人：UNIVERSITÄT REGENSBURG

  公开号：WO2016020369A1

  公开（公告）日：2016-02-11

  The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H − L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6).

  本发明涉及小分子化合物及其作为HDAC抑制剂的用途以及在治疗各种疾病（如癌症）中的应用。本发明还涉及合成这些化合物的方法和治疗方法。H - L（HA），其中H是从（头基团1）、（头基团2）、（头基团3）、（头基团4）、（头基团5）和（头基团6）中选择的头基团。
• DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20200071323A1

  公开（公告）日：2020-03-05

  The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.

  该发明提供了公式（I）的化合物：其中变量在规范中定义，或其药用盐，这些化合物可用作JAK激酶抑制剂。该发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗呼吸道疾病的方法。
• HDAC6 inhibitors and their uses
  申请人：Universität Regensburg

  公开号：US10106540B2

  公开（公告）日：2018-10-23

  The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H-L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6).

  本发明涉及小分子化合物及其作为 HDAC 抑制剂和治疗各种疾病（如癌症）的用途。本发明进一步涉及合成化合物的方法和治疗方法。H-L（HA），H 是选自（头组 1）、（头组 2）、（头组 3）、（头组 4）、（头组 5）和（头组 6）的头组。
• 5 to 7 membered heterocyclic amides as JAK inhibitors
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US10836763B2

  公开（公告）日：2020-11-17

  The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.

  本发明提供了式 (I) 的化合物： 或其药学上可接受的盐，可用作 JAK 激酶抑制剂。本发明还提供了包含此类化合物的药物组合物以及使用此类化合物治疗呼吸系统疾病的方法。
• Dimethyl amino azetidine amides as JAK inhibitors
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US10947229B2

  公开（公告）日：2021-03-16

  The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.

  本发明提供了式 (I) 的化合物： 或其药学上可接受的盐，可用作 JAK 激酶抑制剂。本发明还提供了包含此类化合物的药物组合物以及使用此类化合物治疗呼吸系统疾病的方法。